IBDEI0UZ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14253,2)
 ;;=^5005586
 ;;^UTILITY(U,$J,358.3,14254,0)
 ;;=H40.013^^82^775^32
 ;;^UTILITY(U,$J,358.3,14254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14254,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,14254,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,14254,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,14255,0)
 ;;=H40.012^^82^775^33
 ;;^UTILITY(U,$J,358.3,14255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14255,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,14255,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,14255,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,14256,0)
 ;;=H40.011^^82^775^34
 ;;^UTILITY(U,$J,358.3,14256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14256,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,14256,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,14256,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,14257,0)
 ;;=H52.03^^82^775^41
 ;;^UTILITY(U,$J,358.3,14257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14257,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,14257,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,14257,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,14258,0)
 ;;=H52.02^^82^775^42
 ;;^UTILITY(U,$J,358.3,14258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14258,1,3,0)
 ;;=3^Hypermetropia,Left Eye
 ;;^UTILITY(U,$J,358.3,14258,1,4,0)
 ;;=4^H52.02
 ;;^UTILITY(U,$J,358.3,14258,2)
 ;;=^5006261
 ;;^UTILITY(U,$J,358.3,14259,0)
 ;;=H52.01^^82^775^43
 ;;^UTILITY(U,$J,358.3,14259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14259,1,3,0)
 ;;=3^Hypermetropia,Right Eye
 ;;^UTILITY(U,$J,358.3,14259,1,4,0)
 ;;=4^H52.01
 ;;^UTILITY(U,$J,358.3,14259,2)
 ;;=^5006260
 ;;^UTILITY(U,$J,358.3,14260,0)
 ;;=H59.41^^82^775^44
 ;;^UTILITY(U,$J,358.3,14260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14260,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
 ;;^UTILITY(U,$J,358.3,14260,1,4,0)
 ;;=4^H59.41
 ;;^UTILITY(U,$J,358.3,14260,2)
 ;;=^5006426
 ;;^UTILITY(U,$J,358.3,14261,0)
 ;;=H59.42^^82^775^45
 ;;^UTILITY(U,$J,358.3,14261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14261,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 2
 ;;^UTILITY(U,$J,358.3,14261,1,4,0)
 ;;=4^H59.42
 ;;^UTILITY(U,$J,358.3,14261,2)
 ;;=^5006427
 ;;^UTILITY(U,$J,358.3,14262,0)
 ;;=H59.43^^82^775^46
 ;;^UTILITY(U,$J,358.3,14262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14262,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 3
 ;;^UTILITY(U,$J,358.3,14262,1,4,0)
 ;;=4^H59.43
 ;;^UTILITY(U,$J,358.3,14262,2)
 ;;=^5006428
 ;;^UTILITY(U,$J,358.3,14263,0)
 ;;=H59.40^^82^775^47
 ;;^UTILITY(U,$J,358.3,14263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14263,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Unspec
 ;;^UTILITY(U,$J,358.3,14263,1,4,0)
 ;;=4^H59.40
 ;;^UTILITY(U,$J,358.3,14263,2)
 ;;=^5006425
 ;;^UTILITY(U,$J,358.3,14264,0)
 ;;=H54.8^^82^775^48
 ;;^UTILITY(U,$J,358.3,14264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14264,1,3,0)
 ;;=3^Legal Blindness,as Defined in USA
 ;;^UTILITY(U,$J,358.3,14264,1,4,0)
 ;;=4^H54.8
 ;;^UTILITY(U,$J,358.3,14264,2)
 ;;=^5006369
 ;;^UTILITY(U,$J,358.3,14265,0)
 ;;=H40.1231^^82^775^35
 ;;^UTILITY(U,$J,358.3,14265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14265,1,3,0)
 ;;=3^Glaucoma,Low-Tension,Mild Stage,Bilateral
 ;;^UTILITY(U,$J,358.3,14265,1,4,0)
 ;;=4^H40.1231
 ;;^UTILITY(U,$J,358.3,14265,2)
 ;;=^5005768
 ;;^UTILITY(U,$J,358.3,14266,0)
 ;;=H40.1232^^82^775^36
 ;;^UTILITY(U,$J,358.3,14266,1,0)
 ;;=^358.31IA^4^2
